First-in-Class Treatment for Narcolepsy Targeting the Root Cause Approved

The U.S. Food and Drug Administration (FDA) has granted final approval for Takeda Pharmaceutical's 'Orzeyful' (active ingredient: ovexorexton) as a treatment for adult Narcolepsy Type 1 (NT1). Orzeyful is the world's first orexin receptor 2 (OX2R) selective agonist that directly targets the root cause of narcolepsy, which is the loss of orexin-secreting cells in the brain. Existing wakefulness-promoting agents, such as methylphenidate, have only provided symptomatic relief by temporarily alleviating sleepiness. In contrast, Orzeyful is expected to revolutionize the treatment of narcolepsy by directly activating the lost signaling pathway and fundamentally improving the quality of life for patients.

Overwhelming Efficacy Demonstrated Through Phase 3 Clinical Data

This approval is based on robust data obtained from the global Phase 3 trials, 'FirstLight' and 'RadiantLight'. In the clinical trials, the Orzeyful 2mg group showed a statistically significant increase in sleep latency in the Maintenance of Wakefulness Test (MWT) at week 12 compared to the control group (p < 0.001). In particular, the Epworth Sleepiness Scale (ESS) score, which assesses patients' daily sleepiness, was significantly improved to a normal range of 10 or less. Furthermore, the frequency of cataplexy, a key symptom of Narcolepsy Type 1, was reduced by more than 80%, demonstrating excellent efficacy in controlling symptoms.

Reshaping the Existing Market and Securing a Leading Position in the Orexin Market

The launch of Orzeyful is expected to intensify competition for market leadership with Jazz Pharmaceuticals' 'Xyrem' and 'Xywav', which have been the dominant players in the narcolepsy treatment market. Existing drugs containing oxybate have been distributed under strict regulations due to their potential for abuse and limited ease of use. However, Orzeyful is expected to have better patient access due to its favorable safety profile. The global narcolepsy treatment market is currently estimated at approximately $3.5 billion to $4.4 billion by 2025-2026, and is projected to grow to as much as $9.3 billion by 2035, driven by the commercialization of orexin-targeted therapies. Takeda is now poised to capitalize on this opportunity and secure a strong leading position in the orexin agonist field.

Future Commercialization Schedule and Expectations for the Follow-up Pipeline

Following FDA approval, Orzeyful is scheduled to be launched in the U.S. market within approximately 90 days after completion of the scheduling process by the U.S. Drug Enforcement Administration (DEA). Takeda has overcome the challenges of the previous candidate, 'TAK-994', which was discontinued due to hepatotoxicity issues during clinical trials, and has successfully commercialized 'TAK-861 (Orzeyful)'. The company plans to use this approval for Narcolepsy Type 1 as a stepping stone to expand into Narcolepsy Type 2 and other hypersomnia indications, which is expected to further increase its long-term pipeline value. The narcolepsy patient community has also welcomed the emergence of a treatment that targets the underlying mechanism, and early market penetration is expected to be high.